Dr. Stark has worked in Clinical Pharmacology since 2000 and Early Drug Development since 2010 both in industry and Clinical Research Organization. She is a trained Biologist with a Diploma in Germany specializing in Physiology and received a PhD in Immunology from Goettingen University. Sandra joined Parexel Early Phase (EP) in 2004 and has held a number of positions, initially with Project Management, then 4 years in EP Business Development, moving as a founding member into Early Product Development as a Portfolio Director where she was heading Therapeutic Area Immunology/Rare Diseases for 8 years and finally moving into role of Head EPCU Berlin. Besides her Unit head role she is also responsible for Early Phase in Asia-Pacific Region.